• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Alexion Plans First Biologics Facility Outside US


Alexion will construct a biologics facility in Ireland that is its first outside the US.


Alexion Pharmaceuticals plans to significantly expand its operations in Ireland by constructing the company’s first biologics manufacturing facility outside the United States, the company announced on May 11, 2015. This €450 million (approximately US$500 million), four-year project, which will be constructed at Alexion’s College Park site in Blanchardstown, is expected to create approximately 200 additional full-time jobs on completion, which will bring Alexion’s total workforce in Ireland to almost 500 employees.

Since first entering Ireland in 2013, Alexion has invested €130 million (US$145 million) in two facilities-a vial fill-finish facility in Athlone and a global supply-chain facility at College Park. Phase one of the College Park facility, which will comprise the Global Supply Chain headquarters, laboratories, packaging, and warehousing operations, is expected to be operational by year-end. 

Recent Videos
Related Content